Coherus Biosciences (8C5) AI Stock Analysis

Coherus Biosciences

(Frankfurt:8C5)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

LOQTORZI commercial growthLOQTORZI is showing measurable commercial traction, with sequential sales growth, improving patient starts and better treatment duration. If management sustains the guided 10%–15% quarterly growth range, the product can become a more meaningful recurring revenue base.

Negative Factors

Severe cash burnLarge recurring operating and free-cash-flow losses mean the business is not currently self-funding. Even with cost reductions and stated funding through key readouts, continued burn increases dependence on financing, asset proceeds or faster commercial improvement.

Coherus Biosciences (8C5) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 115.78M
Dividend Yield: ―
Average Volume (3M): 200
Price to Earnings (P/E): -0.7
Beta (1Y): 1.14
Revenue Growth: -66.77%
EPS Growth: 31.35%
Country: Germany
Employees: 144
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Coherus Biosciences Business Overview & Revenue Model

Company Description

Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies...

Coherus Biosciences Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|% Change Since:-36.67%|Next Earnings Date:Nov 08, 2026

Earnings Call SentimentPositive

The call conveys meaningful progress across clinical and commercial fronts: robust enrollment across multiple studies, encouraging early TAGMO signals with biomarker directionality, solid commercial momentum for LOQTORZI (+15% QoQ sales) and sustained cost/liability reductions. Offsetting risks include a sizable quarter-over-quarter cash decline (~ -36.9%), an unachieved $37.5M milestone in Q2, immature clinical datasets that could change post-data cleaning, and ongoing commercial adoption/dosing frictions. On balance, the highlights (pipeline enrollment, early efficacy signals, revenue growth, expense reductions and liability improvements) outweigh the lowlights, though near-term execution and data maturation remain critical.

Positive Updates

Clinical Enrollment Milestones

Multiple programs have completed full enrollment: CADILYZE (Casdozokitug) first-line HCC (72 patients fully enrolled) and TAGMO cohorts in head and neck squamous cell carcinoma and colorectal cancer have completed enrollment. Additional TAGMO cohorts in upper GI and esophageal SCC nearing accrual/completing enrollment. A new TAGMO combination cohort with pasritamig is on track to initiate in the fall.

Negative Updates

Quarterly Cash Decline

Total cash, cash equivalents and investments declined from $167.0M at Q1 to $105.3M at Q2 (≈ -36.9%). Management attributed about $39M of the decrease to TSA obligations, but the cash reduction increases sensitivity to upcoming milestones and operating needs.

Company Guidance

Management reiterated full‑year 2026 operating expense guidance of $170–$175 million and expects LOQTORZI revenue of $57–62 million for 2026, with average quarterly LOQTORZI growth of 10–15% (Q2 LOQTORZI net sales were $13.6M, +15% QoQ) and targets of a $15M quarter in 2026, a $30M quarter in 2027 and a peak‑market‑share quarter by 2028. Q2 R&D from continuing operations was $21.4M (down from $26.3M YoY) and SG&A was $21.0M (down from $26.0M YoY), marking six consecutive quarters of declining SG&A; these cost improvements follow the divestiture that reduced secured and convertible debt by >90%. Cash, cash equivalents and investments were $105.3M at quarter end (vs. $167M at Q1), a ~$61.7M decline of which roughly $39M was attributable to TSA obligations; accrued rebates/reserves fell from $28.8M to $14.9M and TSA payables/accrued liabilities from $61.6M to $22.7M. Management reiterated they believe they are sufficiently funded through key data readouts in 2026–2027; the $37.5M earn‑out milestone from the UDENYCA sale was not achieved in Q2 but remains eligible heading into Q3.

Coherus Biosciences Risk Analysis

Coherus Biosciences disclosed 68 risk factors in its most recent earnings report. Coherus Biosciences reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

2 New Risks

1.Risk Factor SummaryQ3, 2024

2.There are risks and uncertainties associated with the CIMERLI TSA and YUSIMRY TSA, one or more of which could have a material adverse effect on our business, financial condition, results of operations, cash flows or stock price.Q3, 2024

Coherus Biosciences Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:8C5 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	78Outperform	$208.68M	10.62	31.61%	―	30.14%	181.54%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IPHA	49Neutral	$156.91M	-2.39	152.56%	―	-24.21%	1.17%
SLS	45Neutral	$1.95B	-40.46	-35.91%	―	―	35.38%
MCRB	42Neutral	$17.60M	-0.77	-60.32%	―	―	71.26%

* Healthcare Sector Average

Performance Comparison

DE:8C5 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:8C5	Coherus Biosciences	0.78	-0.54	-40.96%
SLS	Sellas Life Sciences Group	8.55	6.87	408.93%
PLX	Protalix Biotherapeutics	2.56	0.18	7.56%
MCRB	Seres Therapeutics Inc.	1.83	-10.87	-85.59%
IPHA	Innate Pharma SA Sponsored ADR	1.40	-0.42	-23.08%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Coherus Biosciences AI Stock Analysis